Immunomodulation in endometrial cancer

International Journal of Gynecological Cancer

Volumn 19, Issue 4, 2009, Pages 734-740

  Brooks, Nicole ^a   Pouniotis, Dodie S ^a  

^a RMIT UNIVERSITY   (Australia)

Author keywords

Endometrial cancer; Immunomodulation; Immunotherapy

Indexed keywords

ANGIOGENIC FACTOR; CANCER TESTIS ANTIGEN; CYTOKINE; DOXORUBICIN; INTERLEUKIN 4; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NY ESO 1 ANTIGEN; PACLITAXEL; TRASTUZUMAB; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

ANGIOGENESIS; APOPTOSIS; CANCER CELL; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CANCER PATIENT; CD4+ T LYMPHOCYTE; CELL MOTILITY; CYTOTOXIC T LYMPHOCYTE; ENDOMETRIUM CANCER; HUMAN; IMMUNE DYSREGULATION; IMMUNE RESPONSE; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MACROPHAGE; MELANOMA; METASTASIS; NATURAL KILLER CELL; ONCOGENE NEU; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; REVIEW; T LYMPHOCYTE; TUMOR GROWTH; TUMOR IMMUNITY;

ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS; IMMUNOTHERAPY;

EID: 67651049026     PISSN: 1048891X     EISSN: None     Source Type: Journal    
DOI: 10.1111/IGC.0b013e3181a12f7f     Document Type: Review

References (95)

1. Ryan AJ, Susil B, Jobling TW, et al. Endometrial cancer. Cell Tiss Res. 2005;322:53-61.
2. Robertson G. Screening for endometrial cancer. Med J Aust. 2005;178: 657-659.
3. Prat J, Gallardo A, Cuatrecasas M, et al. Endometrial carcinoma: pathology and genetics. Pathology. 2007;39:72-87.
4. Oehler MK, Fung A, Jobling TW. Advances in the treatment of endometrial cancer. J Br Menopause Soc. 2005;11:18-22.
5. Amant F, Moerman P, Neven P, et al. Endometrial Cancer. Lancet. 2005;366:491-505.
6. Jennings-Dozier K, Mahon SM. Cancer Prevention, Detection, and Control: A Nursing Perspective. Pittsburgh: Oncology Nursing Society; 2002.
7. Santin AD, Zhan F, Cane S, et al. Gene expression fingerprint of uterine serous papillary carcinoma: identification of novel molecular markers for uterine serous cancer diagnosis and therapy. Br J Cancer. 2005;92:1561-1573.
8. Ellenson LH, Wu TC. Focus on endometrial and cervical cancer. Cancer Cell. 2004;5:533-538.
9. Santin AD, Bellone S, Van Stedum S, et al. Amplification of c-erbB2 oncogene: a major prognostic indicator in uterine serous papillary carcinoma. Cancer. 2005;104:1391-1397.
10. Santin AD, Bellone S, Ravaggi A, et al. Induction of tumour-specific CD8 (+) cytotoxic T lymphocytes by tumour lysate-pulsed autologous dendritic cells in patients with uterine serous papillary cancer. Br J Cancer. 2002;86:151-157.
11. Santin AD, Bellone S, Van Stedum S, et al. Determination of HER2/neu status in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry and fluorescence in situ hybridization. Gynecol Oncol. 2005;98:24-30.
12. Ko EC, Wang X, Ferrone S. Immunotherapy of malignant diseases. Int Arch All Immunol. 2003;132:294-309.
13. Lizee G, Radvanyi LG, Overwijk WW, et al. Immunosuppression in melanoma immunotherapy: potential opportunities for intervention. Clin Cancer Res. 2006;17:2359s-2365s.
14. Fowler JM, Ramirez N, Cohn DE, et al. Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: tissue microarray analysis. Am J Obstet Gynecol. 2005;192:1262-1273.
15. Slater M, Cooper M, Murphy CR. Human growth hormone and interleukin-6 are upregulated in endometriosis and endometrioid adenocarcinoma. Acta Histochemica. 2006;108:13-18.
16. Das H, Koizumi T, Suqimoto T, et al. Quantitation of Fas and Fas ligand gene expression in human ovarian, cervical and endometrial carcinomas using real-time quantitative RT-PCR. Br J Cancer. 2000;82:1682-1688.
17. Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3:991-998.
18. Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol. 2001;2:293-299.
19. Gajewski TF, Meng Y, Blank C, et al. Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006;213:131-145.
20. Whiteside TL. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol. 2006;16:3-15.
21. Pinzon-Charry A, Maxwell T, Lopez JA. Dendritic cell dysfunction in cancer: a mechanism for immunosuppression. Immunol Cell Biol. 2005;83:451-461.
22. Pinzon-Charry A, Ho CS, Maxwell T, et al. Numerical and functional defects of blood dendritic cells in early-and late-stage breast cancer. Br J Cancer. 2007;97:1251-1259.
23. Ugurel S, Ulig D, Pföhler C, et al. Down-regulation of HLA class II and costimulatory CD86/B7-2 on circulating monocytes from melanoma patients. Cancer Immun Immunother. 2004;53:551-559.
24. Luczyriski W, Stasiak-Barmuta A, Krawczuk-Rybak M, et al. Monocytes in children with leukemias and lymphomas-down-regulation of HLA and costimulatory molecules. Acta Biochemica Polonica. 2004;51: 1067-1073.
25. Mytar B, Woloszyn M, Szatanek R, et al. Tumor cell-induced deactivation of human monocytes. J Leukoc Biol. 2003;74:1094-1101.
26. Whiteside TL. Apoptosis of immune cells in the tumor microenvironment and peripheral circulation of patients with cancer: implications for immunotherapy. Vaccine. 2002;20:A46-51.
27. Liakou CI, Narayanan S, Ng Tang D, et al. Focus on TILs: prognostic significance of tumor infiltrating lymphocytes in human bladder cancer. Cancer Immun. 2007;7:10-10.
28. Chiou S-H, Sheu BC, Chang WC, et al. Current concepts of tumor-infiltrating lymphocytes in human malignancies. J Reprod Immunol. 2005;67:35-50.
29. Villella JA, Cohen S, Smith DH, et al. HER-2/neu overexpression in uterine papillary serous cancers and its possible therapeutic implications. Int J Gynecol Cancer. 2006;16:1897-1902.
30. Bosscher JR, Ger0el-Taylor C, Watkins CS, et al. Epitope recognition by anti-cathepsin D autoantibodies in endometrial cancer patients. Gynecol Oncol. 2001;81:138-143.
31. Chang WC, Huang SC, Torng PL, et al. Expression of inhibitory natural killer receptors on tumor-infiltrating CD8+ T lymphocyte lineage in human endometrial carcinoma. Int J Gynecol Cancer. 2005;15: 1073-1080.
32. Guerra N, Guillard M, Angevin E, et al. Killer inhibitory receptor (CD158b) modulates the lytic activity of tumor-specific T lymphocytes infiltrating renal cell carcinomas. Blood. 2000;95:2883-2889.
33. Cerwenka A, Lanier LL. Natural killer cells, viruses and cancer nature reviews. Immunology. 2001;1:41-49.
34. Sheu B-C, Chiou SH, Lin HH, et al. Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+T lymphocytes in human cervical carcinoma. Cancer Res. 2005;65:2921-2929.
35. Speiser DE, Pittet MJ, Valmori D, et al. In vivo expression of natural killer cell inhibitory receptors by human melanoma-specific cytolytic T lymphocytes. J Exp Med. 1999;190:775-782.
36. Sheu BC, Hsu SM, Ho HN, et al. Reversed CD4/CD8 ratios of tumor-infiltrating lymphocytes are correlated with the progression of human cervical carcinoma. Cancer. 1999;86:1537-1543.
37. Kondratiev S, Sabo E, Yakirevich E, et al. Intratumoral CD8+T lymphocytes as a prognostic factor of survival in endometrial carcinoma. Clin Cancer Res. 2004;10:4450-4456.
38. Miyatake T, Tringler B, Liu W, et al. B7-H4 (DD-O110) is overexpressed in high risk uterine endometrioid adenocarcinomas and inversely correlated with tumor T-cell infiltration. Gynecol Oncol. 2007;106:119-127.
39. Knutson KL, Disis ML. Tumor antigen-specific T helper cells in cancer immunity and immunotherapy. Cancer Immunol Immunother. 2005; 54:721-728.
40. Punnonen R, Teisala K, Kuoppala T, et al. Cytokine production profiles in the peritoneal fluids of patients with malignant or benign gynecologic tumors. Cancer. 1998;83:788-796.
41. Fischer WH, thor Straten P, Terheyden P, et al. Function and dysfunction of CD4+T cells in the immune response to melanoma. Cancer Immun Immunother. 1999;48:363-370.
42. Scambia G, Testa U, Panici PB, et al. Interleukin-6 serum levels in patients with gynecological tumors. Int J Cancer. 1994;57:318-323.
43. Shurin MR, Lu L, Kalinski P, et al. Thl/Th2 balance in cancer, transplantation, and pregnancy. Semin Immunopathol. 1999;21: 339-359.
44. Chopra V, Dinh TV, Hannigan EV. Serum levels of interleukins, growth factors, and angiogenin in patients with endometrial cancer. J Cancer Res Clin Oncol. 1997;123:167-172.
45. Bellone S, Watts K, Cane S, et al. High serum levels of interleukin-6 in endometrial carcinoma are associated with uterine serous papillary histology, a highly aggressive and chemotherapy-resistant variant of endometrial cancer. Gynecol Oncol. 2005;98:92-98.
46. Thornton AM. Signal transduction in CD4+CD25+ regulatory T cells: CD25 and IL-2. Front Biosci. 2006;11:921-927.
47. Misra N, Bayry J, LaCroix-Desmazes S, et al. Cutting edge: human CD4+CD25+T cells restrain the maturation and antigen-presenting function of dendritic cells. J Immunol. 2004;172:4676-4680.
48. Wang R-F. Functional control of regulatory T cells and cancer immunotherapy. Semin Cancer Biol. 2006;16:106-114.
49. Fattorossi A, Battaglia A, Ferrandina G, et al. Lymphocyte composition of tumor draining lymph nodes from cervical and endometrial cancer patients. Gynecol Oncol. 2004;92:106-115.
50. Giatromanolaki A, Bates GJ, Koukourakis MI, et al. The presence of tumor-infiltrating FOXP3+ lymphocytes correlates with intratumoral angiogenesis in endometrial cancer. Gynecol Oncol. 2008;110:216-221.
51. Deleted in proof.
52. GordonI O, Freedman RS. Defective antitumor function of monocyte-derived macrophages from epithelial ovarian cancer patients. Clin Cancer Res. 2006;12:1515-1524.
53. Bingle L, Brown NJ, Lewis CE. The role of tumour-associated macrophages in tumour progression: implications for new anticancer therapies. J Pathol. 2002;196:254-265.
54. Condeelis J, Pollard JW. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell. 2006;124:263-266.
55. Tanaka Y, Kobayashi H, Suzuki M, et al. Thymidine phosphorylase expression in tumor-infiltrating macrophages may be correlated with poor prognosis in uterine endometrial cancer. Human Pathol. 2002;33: 1105-1113.
56. Kamat AA, Merritt WM, Coffey D, et al. Clinical and biological significance of vascular endothelial growth factor in endometrial cancer. Clin Cancer Res. 2007;13:7487-7495.
57. Fujimoto J, Aoki I, Khatun S, et al. Clinical implications of expression of interleukin-8 related to myometrial invasion with angiogenesis in uterine endometrial cancers. Ann Oncol. 2002;13:430-434.
58. Salvesen HB, Akslen LA. Significance of tumour-associated macrophages, vascular endothelial growth factor and thrombospondin-1 expression for tumour angiogenesis and prognosis in endometrial carcinomas. Int J Cancer. 1999;84:538-543.
59. Hashimoto I, Kodoma J, Seki N, et al. Macrophage infiltration and angiogenesis in endometrial cancer. Anticancer Res. 2000;20: 4853-4856.
60. Ohno S, Ohno Y, Suzuki N, et al. Correlation of histological localization of tumor-associated macrophages with clinicopathological features in endometrial cancer. Anticancer Res. 2004;24:3335-3342.
61. Iurlaro M, Loverro G, Vacca A, et al. Angiogenesis extent and expression of matrix metalloproteinase-2 and-9 correlate with upgrading and myometrial invasion in endometrial carcinoma. Eur J Clin Invest. 1999;29:793-801.
62. Yang X, Dong Y, Zhao J, et al. Increased expression of human macrophage metalloelastase (MMP-12) is associated with the invasion of endometrial adenocarcinoma. Pathol Res Prac. 2007;203: 499-505.
63. Kendrick JE, Estes JM, Straughn JM Jr, et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and its therapeutic potential in breast and gynecologic cancers. Gynecol Oncol. 2007;106: 614-621.
64. Lowe SW, Lin AW. Apoptosis in cancer. Carcinogenesis. 2000;21: 485-495.
65. French LE, Tschopp J. Inhibition of death receptor signaling by FLICE-inhibitory protein as a mechanism for immune escape of tumors. J Exp Med. 1999;190:891-894.
66. Hoffmann TK, Dworacki G, Tsukihiro T, et al. Spontaneous apoptosis of circulating T lymphocytes in patients with head and neck cancer and its clinical importance. Clin Cancer Res. 2002;8:2553-2562.
67. Ryan AE, Lane S, Shanahan F, et al. Fas ligand expression in human and mouse cancer cell lines; a caveat on over-reliance on mRNA data. J Carcinogen. 2006;5:5-11.
68. Hahne M, Rimoldi D, Shröter M, et al. Melanoma cell expression of Fas (Apo-1/CD95) ligand: implicationsfor tumorimmuneescape. Science. 1996;274:1363-1366.
69. Takagi A, Imai A, Horibe S, et al. Lack of evidence for expression of Fas ligand in Fas-bearing tumors. Oncol Rep. 1998;5:377-380.
70. Lejeune F, Liénard D, Matter M, et al. Efficiency of recombinant human TNF in human cancer therapy. Cancer Immun. 2006;6:6-22.
71. Van Themsche C, Lafontaine L, Asselin E. X-Linked inhibitor of apoptosis protein levels and protein kinase C activity regulate the sensitivity of human endometrial carcinoma cells to tumor necrosis factorα-induced apoptosis. Endocrinology. 2008;149:3789-3798.
72. Sadarangani A, Lladros C, Owen G, et al. TRAIL mediates apoptosis in cancerous but not normal primary cultured cells of the human reproductive tract. Apoptosis. 2007;12:73-85.
73. Dolcet X, Llobert D, Pallares J, et al. FLIP is frequently expressed in endometrial carcinoma and has a role in resistance to TRAIL-induced apoptosis. Lab Invest. 2005;85:885-894.
74. Galligan L, Longley DB, McEwan M, et al. Chemotherapy and TRAIL-mediated colon cancer cell death: the roles of p53, TRAIL receptors, and c-FLIP. Mol Cancer Ther. 2005;4:2026-2036.
75. Ino K, Yoshida N, Kajiyama H, et al. Indoleamine 2, 3-dioxygenase is a novel prognostic indicator for endometrial cancer. Br J Cancer. 2006;95:1555-1561.
76. Munn DH, Mellor AL. Indoleamine 2, 3-dioxygenase and tumor-induced tolerance. J Clin Invest. 2007;117:1147-1154.
77. Fallarino F, Grohmann U, Vacca C, et al. T cell apoptosis by tryptophan catabolism. Cell Death Differ. 2002;9:1069-1077.
78. Wicherek L, Popeila TJ, Galazka K, et al. Metallothionein and RCAS1 expression in comparison to immunological cells activity in endometriosis, endometrial adenocarcinoma and endometrium according to menstrual cycle changes. Gynecol Oncol. 2005;99: 622-630.
79. Sonoda K, Miyamoto S, Hirakawa T, et al. Association between RCAS1 expression and microenvironmental immune cell death in uterine cervical cancer. Gynecol Oncol. 2005;97:772-779.
80. Nakashima M, Sonoda K, Watanabe T. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCASI. Nat Med. 1999;5:938-942.
81. Kass R, Agha J, Bellone S, et al. In vitro induction of tumor-specific HLA class I-restricted CD8+ cytotoxic T lymphocytes from patients with locally advanced breast cancer by tumor antigen-pulsed autologous dendritic cells. J Surg Res. 2003;112:189-197.
82. Ferguson A, Moore M, Fox H. Expression of MHC products and leukocyte differentiation antigens in gynaecological neoplasms: an immunohistological analysis of the tumor cells and infiltrating leukocytes. Br J Cancer. 1995;52:551-563.
83. Santin AD, Hermonat PL, Ravaggi A, et al. Development and therapeutic effect of adoptively transferred T cells primed by tumor lysate-pulsed autologous dendritic cells in a patient with metastatic endometrial cancer. Gynecol Obstet Invest. 2000;49:194-203.
84. Slomovitz BM, Broaddus RR, Burke TW, et al. Her-2/neu overexpression and amplification in uterine papillary serous carcinoma. J Clin Oncol. 2004;22:3126-3132.
85. Santin AD, Bellone S, Gokden M, et al. Overexpression of HER-2/neu in uterine serous papillary cancer. Clin Cancer Res. 2002;8:1271-1279.
86. Santin AD, Zhan F, Bellone S, et al. Discrimination between uterine serous papillary carcinomas and ovarian serous papillary tumours by gene expression profiling. Br J Cancer. 2004;90:1814-1824.
87. Odicino FE, Bignolti E, Rossi E, et al. HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization. Int J Gynecol Cancer. 2008;18:14-21.
88. Scanlan MJ, Simpson AJG, Old LJ. The cancer/testis genes: review, standardization, and commentary. Cancer Immun. 2004;4:1-1.
89. Hasegawa K, Koizumi F, Noguchi Y, et al. SSX expression in gynecological cancers and antibody response in patients. Cancer Immun. 2004;4:16-16.
90. Okada T, Akada M, Fujita T, et al. A novel cancer testis antigen that is frequently expressed in pancreatic, lung, and endometrial cancers. Clin Cancer Res. 2006;12:191-197.
91. Resnick MB, Sabo E, Kondratev S, et al. Cancer-testis antigen expression in uterine malignancies with an emphasis on carcinosarcomas and papillary serous carcinomas. Int J Cancer. 2002;101:190-195.
92. Chitale DA, Chitale DA, Jungbluth AA, et al. Expression of cancer-testis antigens in endometrial carcinomas using a tissue microarray. Mod Pathol. 2005;18:119-126.
93. Maraskovsky PP, Sjölander S, Drane PP, et al. NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors. Clin Cancer Res. 2004;10:2879-2890.
94. Jager D, Jager E, Knuth A. Immune responses to tumour antigens: implications for antigen specific immunotherapy of cancer. J Clin Pathol. 2001;54:669-674.
95. Jager E, Karbach J, Gnjatíc S, et al. Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients. Pro Natl Acad Sciences U S A. 2006;103:14453-14458.